Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests if trikafta helps CF patients breathe easier during exercise

NCT ID NCT05279040

Disease control Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 20 adults with cystic fibrosis who are starting Trikafta to see if it reduces shortness of breath and improves exercise performance over two years. Participants will do exercise tests and report their breathing symptoms. The goal is to understand how this medication affects daily life and physical activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The CF patients will be recruited from the St. Paul's Hospital UBC Adult CF Clinic.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene * Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit * Aged 19 years or older * Stable clinical status based on clinical judgment of the treating physician * Forced Expiratory Volume in 1 second (FEV1.0) \< 90% predicted * Body mass index greater than 16 or less than 30 kg/m\^2 * Currently non-smoking or a past smoking history of less than 20 pack-years * Able to read and understand English * Fully vaccinated (at least 2 doses) for Covid-19 Exclusion Criteria: * A disease other than CF that could importantly contribute to dyspnea or exercise limitation * Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians * Contraindications to clinical exercise testing * Use of supplemental oxygen or desaturation less than 85% with exercise * Diagnosis of pneumothorax in the past 4 weeks * History of organ transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic fibrosis Dyspnea lung disorder Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis Lung diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UBC Centre for Heart Lung Innovation, St. Paul's Hospital

    RECRUITING

    Vancouver, British Columbia, V6Z 1Y6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.